Grants and Contributions

The Centre for Research on Pandemic Preparedness and Health Emergencies (CRPPHE) is housed at CIHR with a mandate to grow Canada’s research leadership in preparedness, prevention, response, and recovery from pandemics and public health emergencies, including by building and supporting Canadian research capacity in the field. For more information about it’s mandate and objectives visit the CRPPHE website: https://cihr-irsc.gc.ca/e/52397.html

The Centre for Research on Pandemic Preparedness and Health Emergencies (CRPPHE) is housed at CIHR with a mandate to grow Canada’s research leadership in preparedness, prevention, response, and recovery from pandemics and public health emergencies, including by building and supporting Canadian research capacity in the field. For more information about it’s mandate and objectives visit the CRPPHE website: https://cihr-irsc.gc.ca/e/52397.html

The Centre for Research on Pandemic Preparedness and Health Emergencies (CRPPHE) is housed at CIHR with a mandate to grow Canada’s research leadership in preparedness, prevention, response, and recovery from pandemics and public health emergencies, including by building and supporting Canadian research capacity in the field. For more information about it’s mandate and objectives visit the CRPPHE website: https://cihr-irsc.gc.ca/e/52397.html

The Centre for Research on Pandemic Preparedness and Health Emergencies (CRPPHE) is housed at CIHR with a mandate to grow Canada’s research leadership in preparedness, prevention, response, and recovery from pandemics and public health emergencies, including by building and supporting Canadian research capacity in the field. For more information about it’s mandate and objectives visit the CRPPHE website: https://cihr-irsc.gc.ca/e/52397.html

• The CIHR HIV/AIDS and STBBI Research Initiative (RI), under the leadership of the CIHR Institute of Infection and Immunity (CIHR-III), is responsible for funding research on human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV), chlamydia, gonorrhea, syphilis, and human papilloma virus (HPV). This funding is provided across all CIHR research themes: biomedical research, clinical research, health services research and social, cultural, environmental and population health research.
• Research that focuses on key populations disproportionately affected by HIV/AIDS and STBBI is highly encouraged.
• In alignment with CIHR's commitment to equity, diversity and inclusion (EDI) in the research system, the RI champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.
• This priority announcement will prioritize funding for research on HIV and/or STBBI aligned with the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) in the following research areas:
o Improving health equity by advancing research to understand and address determinants of health, new models of care, or sexual and reproductive health for people living with or at risk of HIV/AIDS and STBBI; or
o Accelerating discovery and innovation by advancing research on innovative technologies for testing and surveillance, interactions among infections and co-morbidities, or design and development of next-generation interventions.
• Should there be no eligible applications relevant to the research areas identified above, applications must be in alignment with the strategic directions of the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) to be funded.

• The CIHR HIV/AIDS and STBBI Research Initiative (RI), under the leadership of the CIHR Institute of Infection and Immunity (CIHR-III), is responsible for funding research on human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV), chlamydia, gonorrhea, syphilis, and human papilloma virus (HPV). This funding is provided across all CIHR research themes: biomedical research, clinical research, health services research and social, cultural, environmental and population health research.
• Research that focuses on key populations disproportionately affected by HIV/AIDS and STBBI is highly encouraged.
• In alignment with CIHR's commitment to equity, diversity and inclusion (EDI) in the research system, the RI champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.
• This priority announcement will prioritize funding for research on HIV and/or STBBI aligned with the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) in the following research areas:
o Improving health equity by advancing research to understand and address determinants of health, new models of care, or sexual and reproductive health for people living with or at risk of HIV/AIDS and STBBI; or
o Accelerating discovery and innovation by advancing research on innovative technologies for testing and surveillance, interactions among infections and co-morbidities, or design and development of next-generation interventions.
• Should there be no eligible applications relevant to the research areas identified above, applications must be in alignment with the strategic directions of the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) to be funded.

• The CIHR Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) will fund applications that are determined relevant to its mandate and research priority areas as described below:
• IMHA mandate areas
o Pain
o Oral Health

• The CIHR Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) will fund applications that are determined relevant to its mandate and research priority areas as described below:
• IMHA mandate areas
o Pain
o Oral Health

• The CIHR Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD) will provide funding for applications in which the objectives and aims are determined to be largely and directly relevant to the INMD mandate as described below:
o CIHR-INMD supports research to enhance health in relation to diet, digestion, excretion, and metabolism; and to address causes, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions and problems associated with hormone, digestive system, kidney, and liver.
• These grants afford principal investigators an opportunity to resubmit their research proposal without the loss of momentum, staff or trainees.

• This Priority Announcement will fund pediatric cancer research that can lead to better outcomes and healthier lives for pediatric cancer patients and their families. The aim is to support promising research projects with the greatest potential for advancing knowledge and improving outcomes.
• Projects must directly and primarily focus on pediatric cancer and pediatric populations (children, adolescents and young adults living with cancer and their families).